Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

Anatomic Stage III Breast Cancer AJCC v8 Clinical Trial

Official title:

A Phase-2, Two-Cohort Trial of Neoadjuvant Nab-Paclitaxel and Alpelisib in Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04216472
• Other study ID #: 2019-0752
• Secondary ID: NCI-2019-0849520
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: February 5, 2020
• Est. completion date: December 31, 2025

Study information

• Verified date: April 2024
• Source: M.D. Anderson Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial studies how well nab-paclitaxel and alpelisib works in treating patients with triple negative breast cancer with PIK3CA or PTEN alterations that does not respond to anthracycline chemotherapy (anthrocycline refractory). Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Alpelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving nab-paclitaxel and alpelisib before surgery may help shrink the tumor before surgery.

Description:

PRIMARY OBJECTIVES:

I. To determine if alpelisib in combination with nab-paclitaxel in the neoadjuvant setting will improve rates of pathologic response (pathological complete response [pCR/RCB-0] or minimal residual disease [RCB-I]) from 5% to 20% in patients with chemotherapy insensitive triple negative breast cancer (TNBC) with PIK3CA alterations (including PTEN loss). (Cohort 1) II. To determine if alpelisib in combination with nab-paclitaxel in the neoadjuvant setting will improve rates of pathologic response (pCR/RCB-0 or RCB-I) from 5% to 20% in patients with chemotherapy insensitive TNBC with PTEN alterations. (Cohort 2)

SECONDARY OBJECTIVES:

I. Determine the radiographic response rate for alpelisib in combination with nab-paclitaxel as measured by ultrasound and/or magnetic resonance imaging (MRI) (partial response + complete clinical response) in chemotherapy insensitive TNBC with PIK3CA (Cohort-1) or PTEN (Cohort-2) alterations.

II. Determine toxicity of alpelisib in combination with nab-paclitaxel given in the neoadjuvant setting following anthracycline based therapy.

III. Determine progression free survival (PFS) at 3 years for patients treated with alpelisib in combination with nab-paclitaxel given in the neoadjuvant setting in chemotherapy insensitive TNBC with PIK3CA (Cohort-1) or PTEN (Cohort-2) alterations.

EXPLORATORY OBJECTIVES:

I. To assess biomarkers of response and resistance to alpelisib and nab-paclitaxel combination.

II. To assess the role of circulating tumor deoxyribonucleic acid (ctDNA) allele fraction in predicting response to alpelisib and nab-paclitaxel in early stage TNBC.

OUTLINE:

Patients receive alpelisib orally (PO) once daily (QD) on days 1-21, and nab-paclitaxel intravenously (IV) over 30 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may then undergo surgery to remove the tumor.

After completion of study treatment, patients are followed up at 30 days, and then periodically until up to 3 years after surgery.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 8
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

• Stage I-III breast cancer

• Confirmed invasive triple-negative breast cancer defined as estrogen receptor (ER) < 10%; progesterone receptor (PR) < 10% by immunohistochemistry (IHC) and HER2 negative by American Society of Clinical Oncology (ASCO)/(College of American Pathologists) CAP guidelines

• Activating mutations in PIK3CA (cohort-1), or loss of function alterations in PTEN by next generation sequencing (NGS) or IHC (cohort-2) (based on MD Anderson Cancer Center [MDACC] Dako 6H2.1 assay)

• Fasting plasma glucose (FPG) =< 140 mg/dL (7.7 mmol/L) and glycosylated hemoglobin (HbA1c) < 6.4 %

• For patients with pre-diabetes (FPG >= 100 mg/dL and/or HbA1c >= 5.7%) at screening, recommend lifestyle changes according to American Diabetes Association (ADA) guidelines. A consultation with a diabetologist is highly recommended

• Chemotherapy insensitive disease as defined by ARTEMIS parameters (=< 70 % volumetric response after four cycles of anthracycline-based therapy)

• Residual primary tumor size of at least 1.0 cm by imaging (ultrasound or MRI) or evidence of lymph node involvement by imaging (ultrasound or MRI) after anthracycline-based neoadjuvant chemotherapy (NACT)

• Received at least one dose of an anthracycline-based NACT. Patients are eligible if therapy was discontinued due to disease progression or therapy intolerance

• Prior to participation on ARTEMIS trial (2014-0185) multigated acquisition scan (MUGA) or echocardiogram showing left ventricular ejection fraction (LVEF) >= 50%

• Absolute neutrophil count (ANC) >= 1.5 x 10^9 /L

• Platelets >= 100 x 10^9 /L

• Hemoglobin (Hb) > 9 g/dL

• Fasting serum amylase =< 2 x upper limit of normal (ULN)

• Fasting serum lipase =< ULN

• Total serum bilirubin =< 1.5 mg/dL

• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN or total bilirubin =< 3.0 x ULN with direct bilirubin within normal range in patients with well documented Gilbert's syndrome

• Serum creatinine =< 1.5 x ULN or and/or creatinine clearance > 50% lower limit of normal (LLN)

• Signed informed consent obtained prior to any screening procedures

• Patients must have at least 2 and no more than 5 weeks between anthracycline-based therapy and start of treatment with alpelisib and nab-paclitaxel

• Patients must have resolution of toxic effect(s) of the most recent prior chemotherapy to grade 1 or less (except alopecia)

• Women of childbearing potential (WCBP) must have a negative pregnancy test within 3 days prior to the first dose of study treatment. WCBP (defined as all women physiologically capable of becoming pregnant) must use highly effective methods of contraception during the study and 12 weeks after. Highly effective contraception methods include a combination of any two of the following:

• Placement of an intrauterine device (IUD) or intrauterine system (IUS)

• Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository

• Total abstinence

• Male/ female sterilization

Exclusion Criteria:

• Pregnant or lactating women

• Patient has a known hypersensitivity to alpelisib or any of its excipients

• Patients with clinically manifest diabetes mellitus (DM) or documented steroid induced DM

• Presence of distant metastatic disease (loco-regional nodal involvement of the ipsilateral axillary, internal mammary and/or supraclavicular nodes is not considered distant metastatic disease

• Prior radiation therapy of the primary breast carcinoma or axillary lymph nodes

• Patient is concurrently using other anti-cancer therapy

• Patients with an established diagnosis of diabetes mellitus type II or uncontrolled type II based on fasting plasma glucose or HbA1c

• Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable or will not be able to complete the entire study

• Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of alpelisib

• Male patients whose sexual partner(s) are WCBP who are not willing to use adequate contraception, during the study and for 4 weeks after the end of treatment

• Patients with > grade 1 peripheral neuropathy

• Patients being treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A within the last 5 days prior to study entry

• Serious concurrent illness or clinically-relevant active infection, including, but not limited to the following:

• Known active hepatitis B or C

• Known human immunodeficiency virus (HIV) infection

• Varicella-zoster virus (shingles)

• Cytomegalovirus infection

• Any other known concurrent infectious disease, requiring IV antibiotics within 2 weeks of study enrollment

• Clinically- significant cardiac disease:

• Recent myocardial infarction (< 6 months prior to day 1)

• Unstable angina pectoris

• Uncontrolled congestive heart failure (New York Heart Association > class II)

• Uncontrolled hypertension

• Prior history of hypertensive crisis or hypertensive encephalopathy

• Uncontrolled cardiac arrhythmias

• Clinically-significant vascular disease (e.g. aortic aneurysm dissecting aneurysm)

• Severe aortic stenosis

• Clinically significant peripheral vascular disease

• Friderica's Corrected QT interval (QTcF) > 470 for females and > 450 for males

• History of neurological conditions that would confound assessment of treatment-emergent neuropathy

• History of hemorrhagic or ischemic stroke within the last 6 months

• Patient with severe liver impairment (Child Pugh score B/C) or cirrhotic liver disease

• Patient has documented history of pneumonitis/interstitial lung disease

• History of acute pancreatitis within 1 year of screening or past medical history of chronic pancreatitis

• Patients who have a history of another primary malignancy, with the exceptions of:

non-melanoma skin cancer, and carcinoma in situ of the cervix, uteri, or breast from which the patient has been disease free for 3 years

• History or evidence of thrombotic or hemorrhagic disorders within 6 months before first study treatment

Related Conditions & MeSH terms

• Anatomic Stage I Breast Cancer AJCC v8
• Anatomic Stage IA Breast Cancer AJCC v8
• Anatomic Stage IB Breast Cancer AJCC v8
• Anatomic Stage II Breast Cancer AJCC v8
• Anatomic Stage IIA Breast Cancer AJCC v8
• Anatomic Stage IIB Breast Cancer AJCC v8
• Anatomic Stage III Breast Cancer AJCC v8
• Anatomic Stage IIIA Breast Cancer AJCC v8
• Anatomic Stage IIIB Breast Cancer AJCC v8
• Anatomic Stage IIIC Breast Cancer AJCC v8
• Breast Neoplasms
• Carcinoma
• Prognostic Stage I Breast Cancer AJCC v8
• Prognostic Stage IA Breast Cancer AJCC v8
• Prognostic Stage IB Breast Cancer AJCC v8
• Prognostic Stage II Breast Cancer AJCC v8
• Prognostic Stage IIA Breast Cancer AJCC v8
• Prognostic Stage IIB Breast Cancer AJCC v8
• Prognostic Stage III Breast Cancer AJCC v8
• Prognostic Stage IIIA Breast Cancer AJCC v8
• Prognostic Stage IIIB Breast Cancer AJCC v8
• Prognostic Stage IIIC Breast Cancer AJCC v8
• Refractory Breast Carcinoma
• Triple Negative Breast Neoplasms
• Triple-Negative Breast Carcinoma

Intervention

Drug:
• Alpelisib
Given PO
• Nab-paclitaxel
Given IV

Locations

Country	Name	City	State
United States	M D Anderson Cancer Center	Houston	Texas

Sponsors (2)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of pathological complete response (pCR/RCB-0)	Will be assessed by the alpelisib in combination with nab-paclitaxel in the neoadjuvant setting will improve rates.	Up to 30 days
Primary	Rate of minimal residual disease (RCB-I)	Will be assessed by the alpelisib in combination with nab-paclitaxel in the neoadjuvant setting will improve rates.	Up to 30 days
Secondary	Radiographic response rate (partial response + complete clinical response)	Will be assessed by the radiographic response rate for alpelisib in combination with nab-paclitaxel	Up to 30 days
Secondary	Incidence of adverse events	Evaluated by Common Terminology Criteria for Adverse Events version 5.	Up to 30 days
Secondary	Progression free survival	Will be estimated using Kaplan-Meier method.	Up to 30 days

External Links

•   MD Anderson Cancer Center Website